Abstract: Primary cutaneous amyloidosis is a chronic itching disease. At present, there is a lack of standard treatment plans for this disease, and traditional therapies such as antihistamines, thalidomide, and local glucocorticoids have poor therapeutic effects. Studies have suggested that correcting the itch-scratch-itch cycle is the key to treating primary cutaneous amyloidosis. Tofacitinib is an oral JAK inhibitor, it can significantly reduce the scratching behavior and the expression of IL-4 and IL-31 in a mouse model of atopic dermatitis. A case of primary skin amyloidosis treated with tofacitinib is reported and the related articles are reviewed.

Key words: tofacitinib, primary cutaneous amyloidosis, JAK inhibitor